InDex Pharmaceuticals Reports Positive PK Results from Cobitolimod in Patients with Ulcerative Colitis
Shots:
- 7 patients treated with cobitolimod (500 mg, rectally). After initial administration plasma concentrations were measured in all 7 patients during a flare, then the degree of clinical remission at week 6 was evaluated on the re-administration of cobitolimod at week 3
- Of 7 patients, 4 patients achieved CR at week 6. After third dose, a second PK analysis was conducted to evaluate systemic uptake of cobitolimod also in patients with remission
- The results showed a limited systemic uptake for both patients in a flare and in remission, with the majority of patients having undetectable levels of cobitolimod in the plasma after 8hrs. Cobitolimod was well tolerated, along with no SAEs were reported
Ref: prnewswire | Image: InDex Pharmaceuticals
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
